Bernal-Reyes R, Bernal-Serrano D

Language: Spanish
References: 14
Page: 6-10
PDF size: 62.80 Kb.

ABSTRACT

Objective: To investigate the Liver Functional Test (LFT) and hepatic ultrasound (US) usefulness in the diagnostic of NASH. Background: NASH is part of NAFLD (non-alcoholic fatty liver disease), this condition can lead to cirrhosis; it is associated with others frequents diseases in Mexico such as type 2 diabetes and obesity. Unfortunately the diagnosis of NASH is not easy, since it must be confirmed by an hepatic biopsy and this requisite can conditionate a subnormal register. Until now, we don’t have programs oriented to detect this disease; even though several high risk populations have been identified. Methods: We compared the results of LFT and hepatic US of ten patients with NASH and ten healthy volunteers. Both groups where matched; the sensibility (S), specificity (Sp) and predictive values (PV) of each test were established. Student t test was used in the statistic analysis. Results: The tests with the most notable difference were aminotransferases (AST, ALT), indirect billirubin (IB) and the US; with S of 100% to IB and US; Sp 100% to aminotransferases; PV+ 100% to ALT and AST, and 71% to US; and PV- 100% to IB and US. Conclusions: LFT and US are useful to detect NASH, the periodic testing of subjects with type 2 diabetes and overweight in risk of NASH is proposed as an effective tool of detection for the cases that require a subsequent study by a gastroenterologist.

REFERENCES

1. Dihel AM. Non Alcoholic Steatohepatitis. Semin Liver Dis 1999; 19(2): 221-9.

2. Brunt EM. Non Alcoholic Steatohepatitis: definition and pathology. Semin Liver Dis 2001; 21(1): 3.

3. Neuschwander-Tetri B. Fatty liver and nonalcoholic steatohepatitis. Clin Cornerstone 2001; 3(6): 47.

4. Younossi Z, Gramlich T, Matteoni Ch. Non-Alcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol 2004; 2(3): 262-5.

5. Angelico F, DelBen M, Conti R, et al. Insulin resistance but not reduced insulin secretion is associated to non alcoholic fatt liver disease (NAFLD). J Hepatol 2003; 38 (Suppl. 2): A3232.

6. Marchesini G, Bugianesi E, Farlani G, et al. Non-alcoholic fatty liver disease, steatohepatitis and metabolic syndrome. Hepatology 2003; 38: 536.

7. Instituto Nacional de Salud Pública y Secretaría de Salud, México. Encuesta Nacional de Enfermedades Crónicas, año 2000. www.insp.mx/ensa2000.

8. El-Serag H. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004; 126(2): 460-8.

9. Bernal-Reyes R, Sáenz-Labra A, Bernardo-Escudero R. Prevalencia de la esteatohepatitis no alcohólica (EHNA), estudio comparativo con diabéticos. Rev Gastroenterol Mex 2000; 65(2): 58-62.

10. Hunt KK, Gaglio PJ, Arons RR. Ethnic differences in the prevalence of NASH in the United States. Gastroenterology 2003; 124: A-702.

11. Levenson H, Greensite F, Hoefs J, et al. Fatty infiltration of the liver. AJR 1991; 156: 307-11.

12. Saadeh S, Younossi Z, Remer E, et al. The utility of radiological imaging in non alcoholic fatty liver disease. Gastroenterology 2002; 123: 745-50.

13. Bacon B, Faravash MJ, Janney CG. Non Alcoholic Steatohepatitis: an expanded clinical entity. Gastroenterology 1994; 1103-6.

14. Hanley A, Williams K, Festa A, et al. Diabetes 2004; 53: 2623.